KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$570.1 million.

  • Amneal Pharmaceuticals' Retained Earnings rose 102.43% to -$570.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$570.1 million, marking a year-over-year increase of 102.43%. This contributed to the annual value of -$607.1 million for FY2024, which is 2384.57% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Retained Earnings of -$570.1 million as of Q3 2025, which was up 102.43% from -$572.4 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Retained Earnings peaked at -$265.6 million during Q2 2021, and registered a low of -$607.1 million during Q4 2024.
  • Moreover, its 5-year median value for Retained Earnings was -$406.2 million (2022), whereas its average is -$439.5 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first surged by 492.06% in 2021, then plummeted by 5029.61% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Retained Earnings (Quarter) stood at -$276.2 million in 2021, then tumbled by 47.06% to -$406.2 million in 2022, then fell by 20.68% to -$490.2 million in 2023, then fell by 23.85% to -$607.1 million in 2024, then rose by 6.09% to -$570.1 million in 2025.
  • Its last three reported values are -$570.1 million in Q3 2025, -$572.4 million for Q2 2025, and -$594.9 million during Q1 2025.